Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL: Rifaximin and Lactulose for Post-TIPS Hepatic Encephalopathy Prevention
NCT04073290Phase 4Recruiting
- Sponsor
- University of Amsterdam
- Start
- Jan 2020
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of rifaximin in hepatic encephalopathy (HE), sponsored by University of Amsterdam. Started Jan 2020; status: recruiting.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT04073290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073290.